Oak Wealth Advisors LLC Buys Shares of 435 Eli Lilly and Company (NYSE:LLY)

Oak Wealth Advisors LLC purchased a new position in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 435 shares of the company’s stock, valued at approximately $336,000.

A number of other institutional investors also recently made changes to their positions in the stock. Berger Financial Group Inc lifted its holdings in shares of Eli Lilly and Company by 14.0% in the fourth quarter. Berger Financial Group Inc now owns 6,544 shares of the company’s stock valued at $5,052,000 after buying an additional 803 shares during the period. Gerber Kawasaki Wealth & Investment Management raised its position in Eli Lilly and Company by 216.8% in the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 6,522 shares of the company’s stock worth $5,035,000 after acquiring an additional 4,463 shares in the last quarter. Rinkey Investments acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $205,000. Prosperity Consulting Group LLC boosted its position in shares of Eli Lilly and Company by 15.7% during the 4th quarter. Prosperity Consulting Group LLC now owns 9,653 shares of the company’s stock valued at $7,452,000 after purchasing an additional 1,308 shares in the last quarter. Finally, Bolthouse Investments LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $540,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

Shares of LLY opened at $884.94 on Friday. The business’s 50-day moving average is $827.69 and its 200-day moving average is $817.91. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company has a market capitalization of $839.07 billion, a price-to-earnings ratio of 75.57, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on LLY shares. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a report on Thursday, January 16th. Cantor Fitzgerald began coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price target on the stock. The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Morgan Stanley cut their target price on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 9th. Finally, Truist Financial increased their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Two equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,017.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.